REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 5
- Part 5: For the preceding part double click ID:nRSH4027Rd
same product class (for example, generic forms of Losec/Prilosec, Lipitor
and Seroquel IR). Additionally, generic manufacturers are often able to
invest more resources in the marketing of their products than we do, due
to their lack of R&D expenses.As well as facing generic competition upon
expiry or loss of IP rights, we also face the risk that generic drug
manufacturers seek to market generic versions of our products prior to
expiries of our patents and/or the Regulatory Exclusivity periods. For
example, as detailed in Note 27 to the Financial Statements from page
186, we are currently facing challenges from numerous generic drug
manufacturers regarding our patents relating to key products, including
Brilinta, Faslodex, Seroquel XR, Byetta, Daliresp, Onglyza and Crestor
- More to follow, for following part double click ID:nRSH4027RfRecent news on AstraZeneca
See all newsREG - AstraZeneca PLC - Notification of Admission of Shares
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for early gastric cancer
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementRCS - Redx Pharma Limited - RXC008 Receives US FDA Fast Track Designation
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
Announcement